1.	Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 04090, NCI-2010-01263, CDR0000438712, FDA R01FD003006-03, CHNMC-04090, NCT00233948
2.	Nelfinavir, a Phase I/Phase II Rectal Cancer Study Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: MEC 07-03-026, NCT00704600
3.	Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000065583, E1D95, AMC-014, NCT00003008
4.	Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 200905704, NCT01065844
5.	Phase I Study of Nelfinavir Mesylate in Patients With Metastatic, Refractory, or Recurrent Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-07-C-0047, NCI-P6880, NCT00436735
6.	Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma Phase: Phase I Type: Treatment Status: Temporarily closed Age: 18 to 65 Sponsor: Other Protocol IDs: 07-09-04/07, EudraCT number 2008-001078-34, NCT00694837
7.	A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: UPCC 01309, NCT01020292
8.	Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: AMCmedonc09/039, NCT01079286